Experimental analysis shows that GSK-3β inhibitors improve social behavior and reduce hyperactivity in Fmr1-KO mice, suggesting implications for Fragile X syndrome.
Glycogen-synthase-kinase-3β (GSK-3β) and microtubule dynamics are implicated in Fragile X syndrome (FXS). We examined behaviors and hippocampal α -tubulin post-translational modifications (PTMs) in Fmr1 -KO male mice without and with chronic administration of the GSK-3β inhibitors SB216763 (30 mg/kg, i.p.) and AF3581 (10 mg/kg, i.p.). Fmr1 -KO male mice and wild-type (WT) were evaluated in the open field, marble-burying, elevated-plus-maze (EPM), novel-object-recognition (NOR) and three-chamber sociability test (3-CST); acetylated α -tubulin (Acet/Total-Tub) and tyrosinated/detyrosinated α -tubulin (Tyr/Glu-Tub) ratios were then analyzed. Fmr1 -KO male showed hyperactivity, excessive marble burying and impaired NOR; Acet/Total-Tub was elevated and Tyr/Glu-Tub reduced vs. WT, indicating reduced microtubule dynamics. In a mixed-sex cohort bred female WT displayed lower Acet/Total-Tub and increased Tyr/Glu-Tub vs. male WT. The Fmr1 -KO-associated decrease in Tyr/Glu-Tub was consistent across sexes. FMRP and synaptic markers were also analyzed in this cohort, spinophilin was found increased in both male and female Fmr 1-KO. Fmr1 -heterozygous females showed no molecular alterations, supporting the protective role of FMRP. Fmr1 -KO male mice received vehicle or GSK-3β inhibitors and were tested in behavioral assays followed by α -tubulin PTMs analysis. Daily vehicle injections appeared to abolish baseline differences in hyperactivity, marble burying and α -tubulin PTMs. Under these conditions both inhibitors reduced marble burying. SB216763 normalized social discrimination in 3-CST, while AF3581 only produced a non-significant positive trend. Neither compound altered α -tubulin PTMs. These results show that GSK-3β inhibition has anti-perseverative and pro-social effects in Fmr1 -KO male mice. However, behavioral and molecular endpoints, such as α -tubulin PTMs, appear to be sensitive to both genetic background and experimental procedures.
No takes yet. Share an insight, caveat, or question.
Kealy et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: